seen from United States
seen from Philippines
seen from Japan
seen from Belgium
seen from Japan
seen from Germany
seen from Japan
seen from Türkiye
seen from Portugal
seen from United States
seen from Türkiye
seen from Russia
seen from Uzbekistan
seen from Türkiye
seen from United States
seen from Malaysia
seen from Philippines
seen from China
seen from Vietnam
seen from Malaysia
Simplify Your Life: Manage Your ALUNBRIG / Brigatinib Order Online
Simplify your routines by effortlessly handling orders through our user-friendly platform. Enjoy the ease of tracking, modifying, and organizing your ALUNRIG / Brigatinib orders online. Embrace efficiency and save time with just a few clicks, making your life simpler and more manageable.
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
As knowledge of lung cancer tumor cell biology has evolved, small-molecule drugs that target specific genetic mutations offer oncologists th
Lung cancer is one of the most common cancers in men and women, and is the leading cause of cancer-related mortality in the United States.1 According to the American Cancer Society, more than 155,000 Americans will die from lung cancer in 2017, representing approximately 25% of all cancer deaths.1 Non–small-cell lung cancer (NSCLC), the most common form of the disease, accounts for 80% to 85% of all lung cancer cases.2
As knowledge of lung cancer tumor cell biology has evolved, small-molecule drugs that target specific genetic mutations offer oncologists the opportunity to treat patients with NSCLC in a personalized fashion.3 Multiple driver oncogenes have been identified in lung cancer, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and KRAS.
Among US patients with advanced NSCLC, approximately 10% have EGFR mutations,3 approximately 23% have KRAS mutations,4 and up to 13% have ALK mutations.5 By identifying these mutations, oncologists can determine which patients can benefit from available targeted therapies.
Crizotinib (XALKori) was the first tyrosine kinase inhibitor (TKI) and alectinib (Alecensa) was the second TKI approved by the US Food and Drug Administration (FDA) for patients with advanced ALK-positive NSCLC.6,7 Although many patients with ALK-rearranged NSCLC respond to a TKI, the resistance rate is high within 1 to 2 years.8 Unlike crizotinib, which does not cross into the brain to target tumors in the central nervous system (CNS),9 alectinib has been shown to have “an effect on tumors that have spread to the brain.”7 Still, additional treatment options for ALK inhibition are needed that can cross the blood–brain barrier.
Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer
Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+)
Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).
The drug was originally discovered by Ariad Pharmaceuticals, which was acquired by Takeda Pharmaceutical Company in February 2017.
Ariad Pharmaceuticals submitted the new drug application (NDA) for Alunbrig to the US Food and Drug Administration (FDA) in August 2016. It was accepted for review in October and the company was granted breakthrough therapy designation. Takeda received accelerated approval in April 2017.
The marketing authorisation application (MAA) for Alunbrig was submitted to the European Medicines Agency (EMA) in February 2017.
Non-small cell lung cancer causes
One of the most common forms of lung cancer, NSCLC occurs when lung cells become abnormal and begin to develop beyond control. In advanced stages, the disease spreads tumours to the brain, bones, adrenal glands, liver, and kidneys.
Smoking is considered to be the major risk factor associated with NSCLC. Symptoms include coughing, chest pain, coughing blood, loss of appetite, shortness of breath, and wheezing.
NSCLC accounts for approximately 85% of the estimated 222,500 new cases of lung cancer diagnosed per year in the US, according to the American Cancer Society’s estimates.
Alunbrig’s mechanism of action
Alunbrig contains a tyrosine kinase inhibitor, which works against multiple kinases including anaplastic lymphoma kinase (ALK), receptor tyrosine kinase, insulin-like growth factor-1 receptor (IGF-1R), and Fms related tyrosine kinase 3 (FLT-3).
ALUNBRIG can cause serious side effects
Learn about the safety of ALUNBRIG® and its possible side effects. Please see Important Safety Information and full Prescribing Information.
Lung problems. ALUNBRIG may cause severe or life-threatening swelling (inflammation) of the lungs any time during treatment and can lead to death. These lung problems happen especially within the first week of treatment with ALUNBRIG. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening symptoms, including:
trouble breathing or shortness of breath
chest pain
cough with or without mucus
fever
High blood pressure (hypertension). ALUNBRIG may cause high blood pressure. Your healthcare provider will check your blood pressure before starting and during treatment with ALUNBRIG. Tell your healthcare provider right away if you get headaches, dizziness, blurred vision, chest pain or shortness of breath.
Slow heart rate (bradycardia). ALUNBRIG may cause very slow heartbeats that can be severe. Your healthcare provider will check your heart rate during treatment with ALUNBRIG. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint during treatment with ALUNBRIG. Tell your healthcare provider if you take any heart or blood pressure medicines.
Vision problems. ALUNBRIG may cause vision problems. Your healthcare provider may stop ALUNBRIG and refer you to an eye specialist if you develop severe vision problems during treatment with ALUNBRIG. Tell your healthcare provider right away if you have any loss of vision or any change in vision, including:
double vision
seeing flashes of light
blurry vision
light hurting your eyes
new or increased floaters
Dec 10, 2019 (The Expresswire) -- Alunbrig Market analyse competitive developments such as expansions, agreements, new product launches, and acquisitions in...
Top News from the IASLC 19th World Conference on Lung Cancer 2018 #WCLC2018
Top News from the IASLC 19th World Conference on Lung Cancer 2018 #WCLC2018
All The Most Important News and Updates form the International Association for the Study of Lung Cancer 19th World Conference – IASLC WCLC 2018 Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
September 24, 2018
Roche has announced results for its investigational medicine entrectinib, from an integrated…
View On WordPress
Top Pharma News of the Week – September 24th
Top Pharma News of the Week – September 24th
All The Most Important Pharmaceutical News Stories Of The Week – September 2018 – Week # 4 FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
September 20, 2018
ACADIA Pharmaceuticals Inc. has announced that the FDA has completed a postmarketing review and…
View On WordPress
